Clinical Trials

55 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05483868 2026-04-15

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Phase 1 Recruiting

55 enrolled

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03528694 2026-04-14

POTOMAC

1,018 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Available

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT07529639 2026-04-14

Tumor Budding and T1 Substaging in Urothelial Bladder Cancer

Not yet recruiting

100 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Disease Progression

NCT05316155 2026-04-13

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

235 enrolled

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06211764 2026-04-13

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-04-13

MoonRISe-1

Phase 3 Recruiting

641 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06877676 2026-04-13

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Approved for marketing

Non-Muscle Invasive Bladder Neoplasms

NCT07309445 2026-04-13

Nova-sTAR

150 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06995677 2026-04-09

SURF302

Phase 2 Recruiting

90 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07511517 2026-04-09

BladMetrix

Active not recruiting

500 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Hypersensitivity

NCT06503614 2026-04-08

ENHANCE

Phase 2 Recruiting

60 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07000084 2026-04-07

GAIN-BCG

Phase 3 Recruiting

330 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07206225 2026-04-07

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Phase 1 Recruiting

294 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06833073 2026-04-06

INTerpath-011

Phase 2 Recruiting

308 enrolled

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05538663 2026-04-03

BRIDGE

870 enrolled

Phase 1 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06253845 2026-04-01

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

20 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07144319 2026-04-01

ENAiBLE

500 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07505615 2026-04-01

VG-INFUSE Tria

Phase 1/2 Completed

20 enrolled

Phase 1/2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT02138734 2026-03-31

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

369 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

40 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06800963 2026-03-27

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

40 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06810141 2026-03-27

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

Available

Non-Muscle Invasive Bladder Neoplasms

NCT07494864 2026-03-27

MiLUT

800 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07495072 2026-03-27

PRO-GAG

Phase NA Recruiting

56 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Cystitis, Interstitial

NCT07225127 2026-03-23

CISTO2

408 enrolled